


A pathway for mild-moderate COVID-19 treatment was developed for BC. Patients at high risk of severe disease are eligible for testing and treatment. Nirmatrelvir/ritonavir (Paxlovid) is available for people who tested positive for COVID-19 and who are at higher risk of hospitalization; remdesivir IV is available if Paxlovid cannot be used due to drug interactions or contraindications. Variations from the pathway will occur as individual clinician discretion is exercised to meet the needs of the individual patient.

The COVID-19 Therapeutics Pathway is available for clinicians to help their patients appropriately navigate through the current available resources so as to receive appropriate, effective and timely care. Key messages include:

- The pathway is grounded in the latest evidence and clinical experience provided by BC’s COVID Therapeutics Committee (CTC).
- Not all patients should be prescribed COVID-19 treatments even they are recommended. These decisions will be made between the patient and clinician.**
- Persons whose symptoms have not resolved within 12 weeks should be re-assessed and considered for [referral to the Post-COVID-19 Interdisciplinary Clinical Care Network](#). Note: a full medical work-up is required before post-COVID referral.

Therapeutic Care Pathway for Mild-Moderate COVID-19



This document provides guidance only; patients defined above are those who may benefit from treatment. Case-by-case assessment is required, and the totality of risk factors needs to be considered when offering treatment. [RACEapp+](#) can be used for clinical consultation services in complex patients requiring Infectious Diseases expertise and input.